Even though tau oligomers of mild-to-moderate dementia patients are eliminated by anti-tau mAbs, Aβ oligomers may not only continue to injure neurons but also enhance the production of pathological tau oligomers as seeds, and must therefore also be eliminated. The gene discussed is MAPT; the disease is dementia.